CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, D0
2026 Annual General Meeting Results - Shareholders Approve All Proposals
Roivant Reports Positive PHocus Study Results for Mosliciguat in PH-ILD Patients
Investor Presentation
FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Annual Report to Security Holders
Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities